Division of Vascular Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Vasc Surg. 2013 Mar;57(3):692-9. doi: 10.1016/j.jvs.2012.08.115. Epub 2013 Jan 23.
Restenosis following tibial artery endovascular interventions (TAEIs) is thought to be benign but is not well characterized. This study examines the consequences and predictors of recurrent stenosis of TAEIs for critical limb ischemia.
All TAEIs for critical limb ischemia performed between 2004 and 2010 were retrospectively reviewed. Restenosis was detected by noninvasive imaging and angiography when indicated. Restenoses were identified and the limb outcomes recorded. Tibial reinterventions were performed only for persistent, worsening, or recurrent tissue loss or rest pain with evidence of recurrence on duplex ultrasound or hemodynamic imaging. The χ test and logistic regression were applied as indicated. One-year patency rates were calculated using the Kaplan-Meier method.
A total of 235 limbs in 210 patients were treated for critical limb ischemia (70% tissue loss, 30% rest pain). Tissue loss included gangrene (49%) and ulcers (51%), and involved the forefoot (80%), the heel (14%), or both (6%). Seventy-eight percent of limbs had Trans-Atlantic InterSociety Consensus C/D lesions, with mean preoperative runoff score of 12. Interventions were isolated tibial (45%) or multilevel (55%) (including tibial). Mean postoperative runoff score improved to 6.6, but restenosis occurred in 96 limbs (41%) at a mean of 4 months. The 1-year primary patency was 59% with a mean follow-up of 9 months. Restenosis presented with a persistent wound (32%), worsened wound (42%), rest pain (16%), or no symptoms (10%). A repeat TAEI was performed in 42 (44%), major amputation in 26 (27%), open bypass in 20 (21%), and observation in eight (8%). The overall amputation rate was 13%, but limb loss was significantly higher in patients with restenosis (n = 26 [27%]) than in patients with no restenosis (n = 5 [4%]; P < .001). Patients with restenosis and tissue loss were more likely to have presented with gangrene (63% vs 38%; P = .0003) but had comparable wound distribution (P = NS). There was a trend toward a higher restenosis rate in patients with renal insufficiency (odds ratio, 5.57; P = .08), but this was unaffected by diabetes, statin therapy, or smoking (P = NS). The rate of repeat intervention after the first reintervention was 36%, with an 87% overall limb salvage rate.
TAEIs can be used successfully to treat patients with critical limb ischemia with acceptable limb salvage rates. Special attention should be given to patients with extensive tissue loss or gangrene because they are at risk for early restenosis and subsequent limb loss. Strict wound and hemodynamic surveillance, wound care, and timely reinterventions are crucial to achieve successful outcomes in this patient population. Amputation or alternative revascularization options, when feasible, should be considered in patients with restenosis and tissue loss given the high rate of limb loss with tibial reinterventions.
经皮腔内血管成形术(TAEI)治疗后发生的再狭窄被认为是良性的,但尚未得到很好的描述。本研究探讨了复发性 TAEI 治疗严重肢体缺血的后果和预测因素。
回顾性分析 2004 年至 2010 年间行 TAEI 治疗的所有严重肢体缺血患者。当有指征时,通过非侵入性影像学和血管造影检查发现再狭窄。确定再狭窄部位,并记录肢体结局。仅对持续性、进行性或复发性组织丢失或静息痛患者进行胫骨再介入治疗,这些患者在双功超声或血流动力学影像学上有复发证据。采用卡方检验和逻辑回归分析。采用 Kaplan-Meier 法计算 1 年通畅率。
210 例患者的 235 条肢体因严重肢体缺血接受治疗(49%组织丢失,30%静息痛)。组织丢失包括坏疽(49%)和溃疡(51%),累及前足(80%)、足跟(14%)或两者(6%)。78%的肢体存在跨大西洋内科学会共识 C/D 病变,术前平均流出道评分为 12 分。干预方式为孤立的胫骨(45%)或多水平(55%)(包括胫骨)。术后平均流出道评分提高至 6.6,但平均 4 个月后发生 96 条肢体(41%)的再狭窄。1 年的原发性通畅率为 59%,平均随访 9 个月。再狭窄的表现为持续的伤口(32%)、恶化的伤口(42%)、静息痛(16%)或无症状(10%)。42 例(44%)患者再次行 TAEI,26 例(27%)患者行大截肢,20 例(21%)患者行开放旁路,8 例(8%)患者行观察。总体截肢率为 13%,但再狭窄患者(n=26[27%])的肢体丢失率明显高于无再狭窄患者(n=5[4%];P<0.001)。有再狭窄和组织丢失的患者更可能出现坏疽(63%比 38%;P=0.0003),但伤口分布无差异(P=NS)。肾功能不全患者的再狭窄发生率呈上升趋势(比值比,5.57;P=0.08),但不受糖尿病、他汀类药物治疗或吸烟的影响(P=NS)。首次再介入后的再次介入率为 36%,整体肢体挽救率为 87%。
TAEI 可成功用于治疗严重肢体缺血患者,肢体挽救率可接受。应特别注意广泛组织丢失或坏疽的患者,因为他们有早期再狭窄和随后肢体丢失的风险。在该患者人群中,严格的伤口和血流动力学监测、伤口护理和及时的再介入对于获得成功的结果至关重要。鉴于胫骨再介入治疗后肢体丢失率较高,对于有再狭窄和组织丢失的患者,应考虑截肢或其他血管重建选择。